Evidence map›Paper›PMID 40389501›Full record

ArticleScientific reports2025

Peripheral eosinophils and immunotherapy response in patients with recurrent or metastatic HNSCC.

Yuexiang Qin, Shanhu Yao, Huimei Huang, Yuyang Xiao, Juncheng Wang, Li She, Changhan Chen, Xingwei Wang, Aijing Luo, Gangcai Zhu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma.International journal of urology : official journal of the Japanese Urological Association · 2026
    Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuexiang Qin *Department of Health Management Medicine, The Third Xiangya Hospital of Central South University, Changsha, 410013, Hunan Province, China.
Shanhu Yao *Department of Radiology, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan Province, China.
Huimei HuangDepartment of Otolaryngology, Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, 410008, Hunan Province, China.
Yuyang XiaoDepartment of Health Management Medicine, The Third Xiangya Hospital of Central South University, Changsha, 410013, Hunan Province, China.
Juncheng WangDepartment of Otolaryngology, Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, 410008, Hunan Province, China.
Li SheDepartment of Otolaryngology, Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, 410008, Hunan Province, China.
Changhan ChenXiangya Hospital, National Medical Metabolomics International Collaborative Research Center, Central South University, Changsha, 410008, Hunan Province, China.
Xingwei WangDepartment of Otolaryngology, Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, 410008, Hunan Province, China.
Aijing LuoKey Laboratory of Medical Information Research, Central South University, Changsha, 410013, Hunan Province, China.
Gangcai ZhuDepartment of Otolaryngology, Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, 410008, Hunan Province, China. qianhudoctor@csu.edu.cn.

Funding

Changsha Distinguished Young Scholars grant kq2209007China Postdoctoral Science Foundation 2022M723559National Natural Science Foundation of China 82173341National Natural Science Foundation of China 82303133Natural Science Foundation of Hunan Province 2021JJ40951Natural Science Foundation of Hunan Province 2022JJ30963Natural Science Foundation of Hunan Province 2023JJ20087Project of Hunan Health Commission B202307017799Project of Hunan Health Commission B202309018525the science and technology innovation Program of Hunan Province 2023RC3082
6 · The paper itself

Abstract

This study investigates the relationship between absolute eosinophil count (AEC) and eosinophil percentage (EOS%) with response rates to immune checkpoint inhibitors (ICIs) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients. The analysis included data from R/M HNSCC patients treated with ICIs at Second Xiangya Hospital (2016-2021), assessing baseline characteristics, tumor specifics, immune-related adverse events, AEC, and EOS%. The correlation between these factors and ICI response rates was evaluated using logistic regression, while survival outcomes were analyzed through Kaplan-Meier curves and Cox models. Among 74 patients, 59 had low AEC and 15 high, with 53 presenting low EOS% and 21 high. Low AEC (44.07% response rate) and EOS% (47.17%) yielded better responses compared to high levels (40% and 33.33%, respectively). Median overall survival was longer for low AEC (22.63 vs. 18.00 months, P < 0.001) and low EOS% (22.07 vs. 19.73 months, P = 0.02). Both low AEC and EOS% correlated with improved survival odds (3.85 and 2.41 times respectively). Lower AEC and EOS% are independently linked to better survival and increased ICI response rates in R/M HNSCC patients, indicating their potential as predictors for ICI treatment outcomes.

Indexed as

EosinophilsHead and Neck NeoplasmsImmune Checkpoint InhibitorsImmunotherapyNeoplasm Recurrence, LocalSquamous Cell Carcinoma of Head and NeckAdultAgedFemaleHumansKaplan-Meier EstimateLeukocyte CountMaleMiddle AgedNeoplasm MetastasisTreatment OutcomeImmune Checkpoint InhibitorsEosinophilsImmunotherapyImmunotherapy responseR/M HNSCCSurvival

Identifiers

PMID40389501
PMCPMC12089525

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.